Related Experiment Video
Updated: May 16, 2025
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
Impact of national volume-based procurement policy on drugs treating chronic Myelogenous Leukemia
Zhao Yang1,2, Yiran Li3, Siyu Liu4
1Peking University First Hospital, Beijing, 100034, China. zhao.yang@bjmu.edu.cn.
Background:
Tyrosine kinase inhibitors (TKIs) have been shown to improve survival rate in chronic myeloid leukemia (CML) patients, but their high costs impose a significant economic burden. This study aimed to evaluate the impact of China's National Volume-Based Procurement (NVBP) policy on the affordability, procurement volume, and costs of these drugs.
Methods:
Based on the data of drug procurement transactions in the database of China Health Insurance Bureau, this study analyzed the impact of National Volume-Based Procurement policy on the affordability, Defined Daily Doses (DDDs), expenditure, and Defined Daily Dose cost (DDDc) of three tyrosine kinase inhibitor (Imatinib, Nilotinib, and Dasatinib) in 25 provinces and hospitals of different levels from January 2019 to December 2020 in China by using an interrupted time series model.
Results:
After the implementation of the procurement policy, the unit price of policy-related Imatinib decreased, leading to increased affordability and a rise of 146.9 thousand DDDs in the month of implementation (p < 0.05), while expenditure remained unchanged. The DDDs and expenditures for Nilotinib and Dasatinib did not show significant changes. The procurement volume of bid-winning generic Imatinib increased by 215.2 thousand DDDs in the month of policy implementation (p < 0.001), with usage share rising from approximately 40% to 80%. Conversely, the DDDs of non-bidding generic and originator drugs significantly decreased post-implementation. The DDDc of Imatinib reduced 69.5 in the month of NVBP implementation (p < 0.001). Furthermore, the DDDc of both bid-winning generic and non-bidding generic Imatinib significantly decreased in the month of policy implementation (p < 0.001).
Conclusions:
The National Volume-Based Procurement policy effectively reduced the unit price of relevant drugs and increased their utilization, thereby improving drug affordability and reducing the financial burden on CML patients requiring long-term treatment.
Related Concept Videos
01:03Drug Control Governance: Regulatory Bodies and Their Impact
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:21Factors Affecting Drug Response: Overview
01:13Parameters Affecting Nonlinear Elimination: Zero-Order Input, First-Order Absorption and Two-Compartment Model
When a drug is administered through a constant intravenous infusion and eliminated via nonlinear pharmacokinetics, it follows zero-order input. For example, oral drugs undergo first-order absorption upon administration and are eliminated through nonlinear pharmacokinetics.
In the case of subcutaneously administered drugs,...
01:25Factors Influencing Drug Absorption: Disease States and Pharmacology
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...